Xenoport Company Profile - Aug 16, 2011

Document Sample
Xenoport Company Profile - Aug 16, 2011 Powered By Docstoc
					Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Xenoport, Inc.
                                                                                        440 Wheelers Farms Road
                                                                                        Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:DANN                                  Key Data

   XenoPort, Inc. is a biopharmaceutical company focused on developing and                   Ticker:
   commercializing a portfolio of internally discovered product candidates, which utilizes   XNPT
   the body's natural nutrient transport mechanisms to improve the therapeutic
   benefits of existing drugs. The product candidates referred to as Transported             2010 Sales:
   Prodrugs are created by modifying the chemical structure of marketed drugs,
                                                                                             2,879,000
   referred to as parent drugs, and are designed to correct limitations in the oral
   absorption, distribution and/or metabolism of the parent drug. The product
   candidate, XP13512 (gabapentin enacarbil), is licensed to Astellas Pharma Inc. in         Major Industry:
   Japan and five Asian countries and to Glaxo Group Limited (GSK), in the United            Drugs, Cosmetics & Health
   States and all other regions globally. Horizant has completed the Phase II clinical       Care
   trials for management of post-herpetic neuralgia (PHN) in the United States, and is
   being evaluated as a prophylactic therapy for migraine headaches in a Phase II b          Sub Industry:
   clinical trial.                                                                           Ethical Drug Manufacturers
                       Stock Chart                                   Officers
                                                              Chief Executive Officer        Country:
                                                               Dr. Ronald W. Barrett         United States

                                                             Senior Vice President           Currency:
                                                           Finance & Chief Financial
                                                                                             U.S. Dollars
                                                                     Officer
                                                                William G. Harris
                                                                                             Fiscal Year Ends:
                                                            Senior Vice President,           December
                                                         Secretary & General Counsel
                                                                Gianna M. Bosko      Employees
                                                                                     108

                                                                                             Exchanges:
                                                                                             NAS

                                                                                             Share Type:
                                                                                             Common

                                                    
				
DOCUMENT INFO
Description: XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates, which utilizes the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The product candidates referred to as Transported Prodrugs are created by modifying the chemical structure of marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. The product candidate, XP13512 (gabapentin enacarbil), is licensed to Astellas Pharma Inc. in Japan and five Asian countries and to Glaxo Group Limited (GSK), in the United States and all other regions globally. Horizant has completed the Phase II clinical trials for management of post-herpetic neuralgia (PHN) in the United States, and is being evaluated as a prophylactic therapy for migraine headaches in a Phase II b clinical trial.
BUY THIS DOCUMENT NOW PRICE: $24.95 100% MONEY BACK GUARANTEED
PARTNER Wright Investors' Service
Wright Investors' Service is an internationally recognized investment management and financial advisory firm headquartered in Milford, Connecticut. For more than 40 years, Wright has used well-defined and sophisticated investment strategies to help institutions, plan sponsors, bank trust departments, trust companies and individual investors achieve their financial objectives through a sensible approach to managing assets that balances risk and return.